In Brief: DynaGen
Executive Summary
DynaGen: Acquires Alpharma subsidiary Able Labs, Cambridge, Mass.-based firm announces Aug. 12. DynaGen is paying $550,000 in cash for the business; Able had $2.5 mil. in 1995 revenues and operated at a loss. DynaGen will acquire rights to 10 approved tablet and suppository ANDA products, a 46,000 sq. ft. manufacturing facility in South Plainfield, N.J. and 45 employees. DynaGen plans to establish a multi-source and specialty pharmaceutical division. It is developing NicErase sublingual lobeline for smoking cessation and anticipates the Able acquisition would provide manufacturing for the product. DynaGen will have $9 mil. in cash after the acquisition...
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth